Previous 10 | Next 10 |
Eli Lilly (NYSE: LLY ) announces positive preliminary results from an NIAID-sponsored clinical trial, ACTT-2 , evaluating the combination of baricitinib and Gilead Sciences' (NASDAQ: GILD ) remdesivir in more than 1,000 hospitalized COVID-19 patients. More news on: Eli Lilly and Com...
INDIANAPOLIS , Sept. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of ...
Massachusetts General Cancer Center awarded $100,000 to launch a patient-centered mobile intervention app for people with chronic graft-versus-host disease (GVHD) Incyte (Nasdaq:INCY) today announced that Massachusetts General Cancer Center is the recipient of the first Incyte Ingenuit...
Calithera signals terminating partnership with Incyte Calithera Biosciences Inc. ( CALA ) reported that it has sent a written intimation to Incyte ( INCY ) terminating their collaboration and licensing agreement. The termination will be effective from September 30. The companies had entere...
Calithera Biosciences (NASDAQ: CALA ) discloses that it has delivered written notice to Incyte (NASDAQ: INCY ) terminating their January 2017 collaboration and license agreement effective September 30. More news on: Calithera Biosciences, Inc., Incyte Corporation, Healthcare stocks...
— Tabrecta is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14) — Tabrecta is the fourth molecule discovered by Incyte scientists to be approved ...
Oncolytics Biotech (NASDAQ: ONCY ) has dosed first patient in Phase 2 IRENE study of Company's pelareorep in combination with Incyte's (NASDAQ: INCY ) anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) in unresectable locally advanced or metastatic triple-negative breast ...
MorphoSys AG (NASDAQ: MOR ) and collaborator/licensee Incyte (NASDAQ: INCY ) announce that Monjuvi (tafasitamab-cxix) has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-cell lymphomas. More news on: MorphoSys AG, Incyt...
MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that Monjuvi ® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer N...
Image source: The Motley Fool. Incyte Corp (NASDAQ: INCY) Q2 2020 Earnings Call Aug 4, 2020 , 8:00 a.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...